Last reviewed · How we verify

CSL Limited — Portfolio Competitive Intelligence Brief

CSL Limited pipeline: 0 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
IgNextGen 16% IgNextGen 16% phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antigens Immunology
IgNextGen 10% IgNextGen 10% phase 3 Intravenous immunoglobulin (IVIG) Fc receptors; multiple pathogenic antigens and antibodies Immunology; Hematology
Ig NextGen 10% Ig NextGen 10% phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antigens Immunology
IntragamP IntragamP phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antibodies Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ADMA Biologics, Inc. · 1 shared drug class
  2. Baxalta now part of Shire · 1 shared drug class
  3. Bio Products Laboratory · 1 shared drug class
  4. Biotest · 1 shared drug class
  5. CSL Behring · 1 shared drug class
  6. Grifols Biologicals, LLC · 1 shared drug class
  7. Grifols Therapeutics LLC · 1 shared drug class
  8. Instituto Grifols, S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CSL Limited:

Cite this brief

Drug Landscape (2026). CSL Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/csl-limited. Accessed 2026-05-14.

Related